Showing 1 posts of 1 posts found.


FDA and NICE approve of first new hyperparathyroidism drug in 12 years

March 8, 2017
Research and Development, Sales and Marketing FDA, NICE, Parsabiv, hyperparathyroidism

The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the first new treatment for patients …

Latest content